PART I Overview We are a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies, including antibody-drug conjugates (ADCs). An ADC consists of a monoclonal antibody conjugated to a cytotoxic drug via a chemical linker. We focus on advancing therapies that leverage our core strengths in understanding biological pathway...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001104659-26-024137 | EDGAR | 79K words |
| 2025-03-06 | 2024-12-31 | 0001558370-25-002402 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001558370-24-003672 | EDGAR | — |
| 2023-03-02 | 2022-12-31 | 0001558370-23-002698 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0001558370-22-002824 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001558370-21-002384 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001558370-20-002566 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001104659-26-092050 | EDGAR | — |
| 2025-11-05 | 2025-09-30 | 0001104659-25-107036 | EDGAR | 18K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010782 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001558370-25-006111 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014869 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001558370-24-010605 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001558370-24-006551 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001558370-23-017429 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001558370-23-013250 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001558370-23-008131 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016275 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012232 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001104659-26-092025 | EDGAR | — |
| 2026-07-14 | 0001104659-26-083326 | EDGAR | — |
| 2026-03-05 | 0001104659-26-024121 | EDGAR | 2K words |
| 2026-01-23 | 0001104659-26-006021 | EDGAR | — |
| 2025-12-19 | 0001104659-25-123305 | EDGAR | — |
| 2025-11-17 | 0001104659-25-112975 | EDGAR | — |
| 2025-11-05 | 0001104659-25-107008 | EDGAR | — |
| 2025-08-25 | 0001558370-25-011752 | EDGAR | — |
| 2025-08-07 | 0001558370-25-010774 | EDGAR | — |
| 2025-07-14 | 0001558370-25-009214 | EDGAR | — |
110 total filings indexed. 81 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001661059 |
| Ticker | NXTC |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nextcure.com |
| Listed | 2019-05-09 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NXTC (~200 tokens, structured JSON with cryptographic provenance)